PROs with Talazoparib + Enzalutamide vs PBO + Enzalutamide in #mCSPC with HRR Gene Alterations: Phase 3 TALAPRO-3. Presented by @AzadOncology @PeterMacCC. #ESMO26 written coverage

UroToday.com· @urotoday · X·2026-10-24 22:00· 16 hours agoScore45

Body · original

PROs with Talazoparib + Enzalutamide vs PBO + Enzalutamide in #mCSPC with HRR Gene Alterations: Phase 3 TALAPRO-3. Presented by @AzadOncology @PeterMacCC. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/3UavnNC #ProstateCancer #PrecisionOncology @myESMO

50 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

2219RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta

https://esmocongress.esmo.org

Source: UroToday.com · x.com